 LEIDEN, Netherlands CAMBRIDGE, Mass., Oct. 04, 2021 GLOBE NEWSWIRE -- ProQR Therapeutics N.V. Nasdaq: PRQR ProQR, a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced the appointment of Theresa Heggie as Chief Commercial Officer reporting to Daniel de Boer, Founder and CEO. In this newly created leadership position, Ms. Heggie will be responsible for overseeing the Companys commercial strategy and global commercial operations. She joins as the Company prepares for the top-line results from its Phase 23 pivotal Illuminate trial of sepofarsen for CEP290-mediated LCA10 in the first half of 2022. 